Zobrazeno 91 - 100
of 160
pro vyhledávání: ''
Autor:
Venessa T. Chin, Ray Asghari, Val Gebski, Lorraine A. Chantrill, Andrew V. Biankin, Nicola Waddell, John Simes, Sonia Yip, Peter Grimison, John F. Pearson, Sandra Harvey, David Miller, Nick Pavlakis, Chee Lee, Amber L. Johns, Scott Mead, Angela Chou, Sean M. Grimmond, Mark Pinese, Lucille Sebastian, Adnan Nagrial, Sanjay Mukhedkar, Danielle Miller, Katrin Marie Sjoquist
Publikováno v:
Molecular Cancer Therapeutics. 12:A75-A75
Background: Less than 5% of patients with metastatic pancreatic cancer survive to 5 years and there have been no major improvements in outcomes over the last 20 years. The use of treatments targeted according to the molecular phenotype of individual
Autor:
Aung Naing, Daniel D. Karp, Veronica R. Holley, Jennifer J. Wheler, Philipp Angenendt, Siqing Fu, Funda Meric-Bernstam, Kevin B. Kim, Apostolia Maria Tsimberidou, Gerald S. Falchook, Ralph Zinner, Vivek Subbiah, Sarina Anne Piha-Paul, Frank Diehl, Razelle Kurzrock, Filip Janku, David S. Hong
Publikováno v:
Molecular Cancer Therapeutics. 12:B26-B26
Background: Actionable mutations confer a survival advantage to cancer cells and can provide therapeutic targets. Cell-free (cf) DNA in the plasma of cancer patients offers an easily obtainable, low-risk, and inexpensive source of biologic material f
Publikováno v:
Molecular Cancer Therapeutics. 12:B27-B27
In the era of precision medicine, matching patients to targeted therapies is a critical goal and novel biomarker strategies must be implemented as new therapeutic options are introduced into the clinic. However, most traditional biomarkers fail to ca
Autor:
Ethan Dmitrovsky
Publikováno v:
Cancer Prevention Research. 6:ED05-03
This session will present on the use of retinoid X receptor (RXR) agonists (rexinoids) for cancer prevention. Several areas will be highlighted. Using lung cancer as a model, both preclinical and clinical evidence for use of RXR-selective ligands in
Autor:
Wen-Pin Chen, Eva Szabo, Rachel Gonzalez, Luz Rodriguez, Jason A. Zell, Daniel L. Gillen, Vanessa Wong, Robert J. Carroll, Richard V. Benya, Asmita Bhattacharya, Frank L. Meyskens, Timothy R. Morgan, Jinah Chung, Steven M. Lipkin
Publikováno v:
Cancer Prevention Research. 6:CN07-01
Colorectal cancer (CRC) progresses through multiple distinct stages that are potentially amenable to chemopreventative intervention. Epidermal Growth Factor Receptor (EGFR) inhibitors can shrink advanced tumors including CRC. There is significant evi
Autor:
Christel Larbouret, Vincent Denis, Nadia Vezzio-Vie, Clara Montagut, Pierre Martineau, Maguy Del Rio, Eve Combes, Laetitia K. Linares, Laetitia Marzi, Gaëlle Thomas, Céline Gongora, Mar Iglesias
Publikováno v:
Molecular Cancer Therapeutics. 12:A62-A62
Cetuximab is used in colorectal cancer (CRC), as targeted therapy against the Epithelial Growth Factor receptor (EGFR), in association with chemotherapy (5-FU and irinotecan). Its binding inhibits signalling pathways downstream to the receptor leadin
Autor:
Francesco Grossi, Angela Alama, Simona Coco, Anna Truini, Cristina Bruzzo, Mariella Dono, Zita Cavalieri
Publikováno v:
Cancer Research. 73:5649-5649
Introduction: Non-small cell lung cancer (NSCLC) represents about 85% of all lung cancers. Almost 20% of NSCLC tumors harbor somatic activating mutations of the tyrosine kinase (TK) encoding domain in EGFR gene (exons 18-21). Patients with EGFR mutat
Abstract 933: Modeling acquired resistance to EGFR-directed therapies in mouse models of lung cancer
Autor:
Katerina Politi, William Pao, Zhongming Zhao, Jungfeng Xia, Valentina Pirazzoli, Elisa de Stanchina
Publikováno v:
Cancer Research. 73:933-933
Seventy percent of patients with Epidermal Growth Factor Receptor (EGFR) mutant lung cancer respond to treatment with the tyrosine kinase inhibitors (TKIs) erlotinib or gefitinib. Despite this high response rate, patients almost inevitably develop re
Autor:
Gabriela Garcia, Gavin MacBeath, Olga Burenkova, William Kubasek, Mark Sevecka, Marisa Wainszelbaum
Publikováno v:
Cancer Research. 73:5464-5464
MM-121/SAR 256212 is a fully human anti ErbB3/HER3 antibody that blocks ligand-induced receptor activation. Formation of EGFR/ErbB3 (ErbB1-3) heterodimers has been implicated as a major driver of tumor growth and survival in non-small cell lung cance
Autor:
Levi A. Garraway, Eliezer M. Van Allen, Vivian Wy Lui, Fan Zhang, Jennifer R. Grandis, Yan Zeng, Hua Li, Gordon B. Mills, Jonas T. Johnson
Publikováno v:
Cancer Research. 73:4565-4565
Activating mutations of EGFR, primarily found in a subgroup of lung cancers, serve as predictive biomarkers for EGFR tyrosine kinase inhibitor (TKI) sensitivity. Clinical responses to EGFR TKIs in other cancers are only moderate and predictive biomar